Tevimbra (tislelizumab-jsgr) — Medica
Colon, Rectal, or Appendiceal Cancer
Initial criteria
- age ≥ 18 years
- ONE of the following: mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease OR DNA polymerase epsilon/delta (POLE/POLD1) mutation
- advanced or metastatic disease
- prescribed by or in consultation with an oncologist
Approval duration
1 year